Emil Marek Heymans Pallesen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emil Marek Heymans Pallesen has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Anders Woetmann
LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
8 shared publications - Carsten Geisler
LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
8 shared publications - Maria Gluud
LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
8 shared publications - Niels Ødum
LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
8 shared publications - Terkild Brink Buus
LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
8 shared publications - Andreas Willerslev-Olsen
LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
7 shared publications
Latest Publications
- Top Cited PapersOpen Access
Staphylococcus aureus Augments Epithelial Skin Barrier Damage Through T Cell Activation in Cutaneous T Cell Lymphoma
Background: Skin barrier dysfunction is central to inflammation and susceptibility to infection in atopic dermatitis (AD). Cutaneous T‐cell lymphoma (CTCL) shares clinical similarities with AD and is also associated with a high prevalence of Staphylococcus aureus ( S. aureus ) colonisation. However, the mechanisms driving skin barrier damage in CTCL and the contribution of bacteria remain poorly understood. Methods: We investigate how the interplay between S. aureus (and staphylococcal enterotoxins (SEs)) and primary malignant‐ and non‐malignant T cells affects keratinocyte expression of skin barrier proteins; in vitro, in an EL4 murine lymphoma model of bacteria‐driven tumour progression, and in CTCL patient lesions colonised with SE‐producing S. aureus before and after bacterial eradication by antibiotic treatment. Results: S. aureus and SEs activate malignant and non‐malignant T cells to release barrier‐repressing cytokines, including IL‐4, IL‐13, IL‐22, and OSM, and JAK‐dependent downregulation of filaggrin and loricrin in keratinocytes. In the EL4 model, bacteria‐colonised tumour‐bearing mice show significant filaggrin loss in tumour‐adjacent epidermis, whereas antibiotic‐treated mice maintain near‐normal expression. Clinically, antibiotic eradication of SE‐producing S. aureus partially restores filaggrin and loricrin expression in three of four patients, paralleling reduced inflammatory signalling. Conclusions: SE‐producing S. aureus promotes skin barrier impairment in CTCL through cytokine‐driven, JAK‐dependent repression of structural proteins in keratinocytes. These findings identify microbial–immune crosstalk as a contributor to CTCL skin pathology and provide mechanistic rationale for strategies targeting S. aureus colonisation as adjunctive therapy in CTCL.
Top Cited PapersOpen AccessStaphylococcus aureus Augments Epithelial Skin Barrier Damage Through T Cell Activation in Cutaneous T Cell Lymphoma
Background: Skin barrier dysfunction is central to inflammation and susceptibility to infection in atopic dermatitis (AD). Cutaneous T‐cell lymphoma (CTCL) shares clinical similarities with AD and is also associated with a high prevalence of Staphylococcus aureus ( S. aureus ) colonisation. However, the mechanisms driving skin barrier damage in CTCL and the contribution of bacteria remain poorly understood. Methods: We investigate how the interplay between S. aureus (and staphylococcal enterotoxins (SEs)) and primary malignant‐ and non‐malignant T cells affects keratinocyte expression of skin barrier proteins; in vitro, in an EL4 murine lymphoma model of bacteria‐driven tumour progression, and in CTCL patient lesions colonised with SE‐producing S. aureus before and after bacterial eradication by antibiotic treatment. Results: S. aureus and SEs activate malignant and non‐malignant T cells to release barrier‐repressing cytokines, including IL‐4, IL‐13, IL‐22, and OSM, and JAK‐dependent downregulation of filaggrin and loricrin in keratinocytes. In the EL4 model, bacteria‐colonised tumour‐bearing mice show significant filaggrin loss in tumour‐adjacent epidermis, whereas antibiotic‐treated mice maintain near‐normal expression. Clinically, antibiotic eradication of SE‐producing S. aureus partially restores filaggrin and loricrin expression in three of four patients, paralleling reduced inflammatory signalling. Conclusions: SE‐producing S. aureus promotes skin barrier impairment in CTCL through cytokine‐driven, JAK‐dependent repression of structural proteins in keratinocytes. These findings identify microbial–immune crosstalk as a contributor to CTCL skin pathology and provide mechanistic rationale for strategies targeting S. aureus colonisation as adjunctive therapy in CTCL.
- Open Access
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Divergent Evolution of Malignant Subclones Maintains a Balance between Induced Aggressiveness and Intrinsic Drug Resistance in T-cell Cancer
Antibodies used (with vendor, catalogue number and RRID)
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Divergent Evolution of Malignant Subclones Maintains a Balance between Induced Aggressiveness and Intrinsic Drug Resistance in T-cell Cancer
Antibodies used (with vendor, catalogue number and RRID)
- Open Access
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S17 from Divergent Evolution of Malignant Subclones Maintains a Balance between Induced Aggressiveness and Intrinsic Drug Resistance in T-cell Cancer
S1 shows sample and analysis pipeline overview. S2 shows malignant-associated gene and surface marker expression in PT17. S3 shows single-cell subclone identification by scTCR-seq, transcriptome and copy-number aberration inference. S4 shows subclonal copy-number aberration co-occurence. S5 shows subclone expression profile stability over time. S6 shows subclonal evolution by matching CITE-seq to flow cytometry. S7 shows validation of inferred CNAs by whole-exome and whole-genome sequencing. S8 shows tissue-associated subclone marker expression in PT09. S9 shows subclonal skin homing/retention markers. S10 shows additional subclonally activated pathways. S11 shows subclonal activation by S. aureus enterotoxins. S12 shows additional S. aureus enterotoxin response signature pathways. S13 shows flow validation of S. aureus enterotoxin response group differences. S14 shows subclonal Romidepsin resistance replicates from same patient at two blood draws. S15 shows subclonal response to inflammatory cytokines and Streptococcal SpeC. S16 shows paired TCR V-gene usage of malignant cells. S17 shows validation of flow cytometry gating and malignant purity estimation.
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S17 from Divergent Evolution of Malignant Subclones Maintains a Balance between Induced Aggressiveness and Intrinsic Drug Resistance in T-cell Cancer
S1 shows sample and analysis pipeline overview. S2 shows malignant-associated gene and surface marker expression in PT17. S3 shows single-cell subclone identification by scTCR-seq, transcriptome and copy-number aberration inference. S4 shows subclonal copy-number aberration co-occurence. S5 shows subclone expression profile stability over time. S6 shows subclonal evolution by matching CITE-seq to flow cytometry. S7 shows validation of inferred CNAs by whole-exome and whole-genome sequencing. S8 shows tissue-associated subclone marker expression in PT09. S9 shows subclonal skin homing/retention markers. S10 shows additional subclonally activated pathways. S11 shows subclonal activation by S. aureus enterotoxins. S12 shows additional S. aureus enterotoxin response signature pathways. S13 shows flow validation of S. aureus enterotoxin response group differences. S14 shows subclonal Romidepsin resistance replicates from same patient at two blood draws. S15 shows subclonal response to inflammatory cytokines and Streptococcal SpeC. S16 shows paired TCR V-gene usage of malignant cells. S17 shows validation of flow cytometry gating and malignant purity estimation.
- Open Access
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Divergent Evolution of Malignant Subclones Maintains a Balance between Induced Aggressiveness and Intrinsic Drug Resistance in T-cell Cancer
Table S1 from Divergent Evolution of Malignant Subclones Maintains a Balance between Induced Aggressiveness and Intrinsic Drug Resistance in T-cell Cancer
- 6 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Divergent Evolution of Malignant Subclones Maintains a Balance between Induced Aggressiveness and Intrinsic Drug Resistance in T-cell Cancer
Table S1 from Divergent Evolution of Malignant Subclones Maintains a Balance between Induced Aggressiveness and Intrinsic Drug Resistance in T-cell Cancer
- Open Access
- 12 September 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 15 (10) , OF1-OF18
Divergent Evolution of Malignant Subclones Maintains a Balance between Induced Aggressiveness and Intrinsic Drug Resistance in T-cell Cancer
Evolution and outgrowth of drug-resistant cancer cells are common causes of treatment failure. Patients with leukemic cutaneous T-cell lymphoma have a poor prognosis because of the development of drug resistance and severe bacterial infections. In this study, we show that most patients with leukemic cutaneous T-cell lymphoma harbor multiple genetically distinct subclones that express an identical clonal antigen receptor but display distinct phenotypes and functional properties. These coexisting malignant subclones exhibit differences in tissue homing, metabolism, and cytokine expression and respond differently to extrinsic factors like Staphylococcus aureus and cancer drugs. Indeed, although S. aureus toxins selectively enhance activation and proliferation of certain subclones, these responsive subclones are also the most intrinsically sensitive to cancer drugs when the stimuli are removed. Consequently, although the divergent evolution of malignant subclones drives aggressiveness, adaptability, and drug resistance by removing extrinsic stimuli and mapping malignant subclones, we can expose inherent vulnerabilities that can be exploited in the treatment of these cancers. Significance: Cancer cells have inherent disparity in hallmark traits, such as aggressiveness and intrinsic drug resistance. We show that segregation of hallmark traits on different coexisting subclones is common and augments adaptability, aggressiveness, and drug resistance of the overall cancer population. Importantly, this segregation exposes vulnerabilities that can be exploited in individualized therapies.
- 12 September 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 15 (10) , OF1-OF18
Open AccessDivergent Evolution of Malignant Subclones Maintains a Balance between Induced Aggressiveness and Intrinsic Drug Resistance in T-cell Cancer
Evolution and outgrowth of drug-resistant cancer cells are common causes of treatment failure. Patients with leukemic cutaneous T-cell lymphoma have a poor prognosis because of the development of drug resistance and severe bacterial infections. In this study, we show that most patients with leukemic cutaneous T-cell lymphoma harbor multiple genetically distinct subclones that express an identical clonal antigen receptor but display distinct phenotypes and functional properties. These coexisting malignant subclones exhibit differences in tissue homing, metabolism, and cytokine expression and respond differently to extrinsic factors like Staphylococcus aureus and cancer drugs. Indeed, although S. aureus toxins selectively enhance activation and proliferation of certain subclones, these responsive subclones are also the most intrinsically sensitive to cancer drugs when the stimuli are removed. Consequently, although the divergent evolution of malignant subclones drives aggressiveness, adaptability, and drug resistance by removing extrinsic stimuli and mapping malignant subclones, we can expose inherent vulnerabilities that can be exploited in the treatment of these cancers. Significance: Cancer cells have inherent disparity in hallmark traits, such as aggressiveness and intrinsic drug resistance. We show that segregation of hallmark traits on different coexisting subclones is common and augments adaptability, aggressiveness, and drug resistance of the overall cancer population. Importantly, this segregation exposes vulnerabilities that can be exploited in individualized therapies.
- Open Access
- 6 March 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (9) , 1757-1768.e3
Endolysin Inhibits Skin Colonization by Patient-Derived Staphylococcus Aureus and Malignant T-Cell Activation in Cutaneous T-Cell Lymphoma
- 6 March 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (9) , 1757-1768.e3
Open AccessEndolysin Inhibits Skin Colonization by Patient-Derived Staphylococcus Aureus and Malignant T-Cell Activation in Cutaneous T-Cell Lymphoma
- Open Access
- 12 January 2023
- Published by American Society of Hematology in Blood
- Vol. 141 (2) , 180-193
Malignant T cells induce skin barrier defects through cytokine-mediated JAK/STAT signaling in cutaneous T-cell lymphoma
Cutaneous T-cell lymphoma (CTCL) is a devastating lymphoid malignancy characterized by the accumulation of malignant T cells in the dermis and epidermis. Skin lesions cause serious symptoms that hamper quality of life and are entry sites for bacterial infection, a major cause of morbidity and mortality in advanced diseases. The mechanism driving the pathological processes that compromise the skin barrier remains unknown. Here, we report increased transepidermal water loss and compromised expression of the skin barrier proteins filaggrin and filaggrin-2 in areas adjacent to TOX-positive T cells in CTCL skin lesions. Malignant T cells secrete mediators (including cytokines such as interleukin 13 [IL-13], IL-22, and oncostatin M) that activate STAT3 signaling and downregulate filaggrin and filaggrin-2 expression in human keratinocytes and reconstructed human epithelium. Consequently, the repression of filaggrins can be counteracted by a cocktail of antibodies targeting these cytokines/receptors, small interfering RNA–mediated knockdown of JAK1/STAT3, and JAK1 inhibitors. Notably, we show that treatment with a clinically approved JAK inhibitor, tofacitinib, increases filaggrin expression in lesional skin from patients with mycosis fungoides. Taken together, these findings indicate that malignant T cells secrete cytokines that induce skin barrier defects via a JAK1/STAT3-dependent mechanism. As clinical grade JAK inhibitors largely abrogate the negative effect of malignant T cells on skin barrier proteins, our findings suggest that such inhibitors provide novel treatment options for patients with CTCL with advanced disease and a compromised skin barrier.
- 12 January 2023
- Published by American Society of Hematology in Blood
- Vol. 141 (2) , 180-193
Open AccessMalignant T cells induce skin barrier defects through cytokine-mediated JAK/STAT signaling in cutaneous T-cell lymphoma
Cutaneous T-cell lymphoma (CTCL) is a devastating lymphoid malignancy characterized by the accumulation of malignant T cells in the dermis and epidermis. Skin lesions cause serious symptoms that hamper quality of life and are entry sites for bacterial infection, a major cause of morbidity and mortality in advanced diseases. The mechanism driving the pathological processes that compromise the skin barrier remains unknown. Here, we report increased transepidermal water loss and compromised expression of the skin barrier proteins filaggrin and filaggrin-2 in areas adjacent to TOX-positive T cells in CTCL skin lesions. Malignant T cells secrete mediators (including cytokines such as interleukin 13 [IL-13], IL-22, and oncostatin M) that activate STAT3 signaling and downregulate filaggrin and filaggrin-2 expression in human keratinocytes and reconstructed human epithelium. Consequently, the repression of filaggrins can be counteracted by a cocktail of antibodies targeting these cytokines/receptors, small interfering RNA–mediated knockdown of JAK1/STAT3, and JAK1 inhibitors. Notably, we show that treatment with a clinically approved JAK inhibitor, tofacitinib, increases filaggrin expression in lesional skin from patients with mycosis fungoides. Taken together, these findings indicate that malignant T cells secrete cytokines that induce skin barrier defects via a JAK1/STAT3-dependent mechanism. As clinical grade JAK inhibitors largely abrogate the negative effect of malignant T cells on skin barrier proteins, our findings suggest that such inhibitors provide novel treatment options for patients with CTCL with advanced disease and a compromised skin barrier.
- 1 October 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (10) , 2449-2458
Staphylococcus aureus Induces Signal Transducer and Activator of Transcription 5‒Dependent miR-155 Expression in Cutaneous T-Cell Lymphoma
- 1 October 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (10) , 2449-2458
Staphylococcus aureus Induces Signal Transducer and Activator of Transcription 5‒Dependent miR-155 Expression in Cutaneous T-Cell Lymphoma